TVGN (Tevogen Bio Holdings) Change In Receivables : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Tevogen Bio Holdings Change In Receivables?

Tevogen Bio Holdings's change in receivables for the quarter that ended in Sep. 2024 was $0.00 Mil. It means Tevogen Bio Holdings's Accounts Receivable stayed the same from Jun. 2024 to Sep. 2024 .

Tevogen Bio Holdings's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.27 Mil. It means Tevogen Bio Holdings's Accounts Receivable increased by $0.27 Mil from Dec. 2022 to Dec. 2023 .

Tevogen Bio Holdings's Accounts Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Tevogen Bio Holdings's liquidation value for the three months ended in Sep. 2024 was $-8.15 Mil.

Tevogen Bio Holdings Change In Receivables Historical Data

The historical data trend for Tevogen Bio Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tevogen Bio Holdings Change In Receivables Chart

Tevogen Bio Holdings Annual Data

Trend

Dec21

Dec22

Dec23

Change In Receivables

-0.27

Tevogen Bio Holdings Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial					-	-	-	-	-

Tevogen Bio Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Tevogen Bio Holdings (NAS:TVGN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Tevogen Bio Holdings's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Tevogen Bio Holdings's accounts receivable are only considered to be worth 75% of book value:

Tevogen Bio Holdings's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.331	-	10.48	+	0.75 * 0	+	0.5 * 0
=	-8.15

Tevogen Bio Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Tevogen Bio Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Tevogen Bio Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (NAS:TVGN) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

G28:Germany

Address

15 Independence Boulevard, Warren, NJ, USA, 07059

Website

https://www.tevogen.com

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.